Pegloticase Use for Uncontrolled Gout in the Dialysis Population Described
New study is the first to characterize pegloticase use in the dialysis population.
Hyperuricemia
No Increased Cardiovascular Risk With Febuxostat vs Allopurinol
In contrast to CARES, FAST found that treatment with febuxostat was not associated with an increase in cardiovascular or all-cause death compared with allopurinol in patients with gout.
Do Uric Acid Lowering Drugs Reduce BP in Hypertensive Patients?
In general, there was low quality evidence from three trials indicating no reduction in systolic (-6.2mmHg, 95% CI: -12.8 to 0.5) or diastolic (-3.9mmHg, 95% CI: -9.2 to 1.4) 24-hour ambulatory BP with uric acid lowering drugs vs. placebo.
New Guidelines Issued for Management of Gout
Approaches for management of gout are presented in a two-part guideline.
